GLP-1 plays an important role in the physiological control of glucose metabolism and energy homeostasis.1 GLP-1 receptor (GLP-1R) agonists are currently in clinical use for the treatment of diabetes mellitus and obesity.2 Because of significant beneficial effects of GLP-1R agonists on the cardiovascular system (including anti-inflammatory, antiatherogenic, positive inotropic, glucose uptake stimulating, and vasodilatory effects),2 GLP-1 has become the most extensively studied incretin. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.